Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that statistically significant data from a randomized controlled study demonstrated that its single-use autologous cell suspension technology ReCell® was safe and effective in skin repigmentation for patients suffering with depigmented skin lesions caused by vitiligo and piebaldism.
Results of the study have been published online and in the July 2015 print issue of the Journal of the American Academy of Dermatology, the official publication of the American Academy of Dermatology (AAD).
